

# SGLT2 Inhibitors: A New Era in Heart Failure Management

Dr. Shailesh Singh

<sup>1</sup>Department of Cardiology

## Abstract

This editorial examines the transformative impact of SGLT2 inhibitors on heart failure outcomes across the spectrum of ejection fraction.

## Introduction

---

Heart failure remains a leading cause of morbidity and mortality worldwide.

## Key Findings

---

The EMPEROR and DAPA-HF trials demonstrated consistent benefits.

---

### Disclosures

The author has no conflicts of interest to disclose.

### Funding

No external funding was received for this work.